All News

Bella Mehta Tweet
bella_mehta
Predictors of first hospitalizations due to disease activity and infections in #lupus 1341 pts from multicenter latin american cohort. 33% with atleast one hospitalization, and 3/4th due to disease activity. @rheumnow #EULAR2023 abt#POS0169 https://t.co/vbJU4220is
Bella Mehta Tweet
bella_mehta
Evaluation of diagnostic performance of ACR 1997, SLICC 2012 and EULAR /ACR diagnostic crieteria in childhood onset #SLE - SLICC highest sensitivity early in the disease, ACR1997 has the highest specificity both at diagnosis ans over time. @RheumNow #EULAR2023 abst#POS0136
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#EULAR2023 #POS1124 My newly diagnosed patients & their carers often expressed heightened anxiety with poor quality web info about #SLE. Thank you @LupusEurope for this wonderful effort 👏. Available in most European languages too @RheumNow https://t.co/cr5Ls117xM
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#EULAR2023 #POS1128 Promising new therapy on the block for #lupus nephritis. A single arm Phase 2a study showed Zetomipozomib, selective immunoproteosome-i + MMF showed about 2/3 pts met =>50% reduction in uPCR at WK24. No safety signal including low IgG or infection @RheumNow https://t.co/0A8cCW5GVV
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#EULAR2023 #OP0226 DORIS remission in #SLE is a goal but may be slight tricky to achieve. Multicentre cohort study showed attainment of LLDAS protected against subsequent Flare and Damage @RheumNow https://t.co/MIypIDW6aE
David Liew Tweet
drdavidliew
We know HCQ adherence is poor in both RA and SLE >50% in this BC 🇹🇩 cohort All despite being such an important medicine What’s super interesting are the trajectories of adherence - and we’d like to understand more about what motivates each group OP0222 #EULAR2023 @RheumNow https://t.co/rbx1l9T36C
Dr. Antoni Chan Tweet
synovialjoints
Antimalarial adherence in RA and SLE showed 4 patterns of adherence over time, with 53% drop off in 1 year, with higher adherence with age, SLE and socioeconomic class, Hoque MR, Abst#0222 #EULAR2023 @RheumNow https://t.co/Bld5kWVQxE
Bella Mehta Tweet
bella_mehta
Fatigue in SLE remains a challenge! Online digital tool - LEAF - Lupus Expert System for Assessment of Fatigue - assement of fatigue PROMs in 1250pts - 80% reported fatigue, 93% found tool helpful @rheumnow #EULAR2023 Need more tools to assess and manage fatigue! abst#OP0230
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#EULAR2023 POS1190-HPR Besides genetic influence, what do patients with #SLE think re: cause of the disease? A survey in N=290 in Sweden showed stress, hormones & infection as the next top 3 causes. Those reported the first two had different education & perceived health @RheumNow https://t.co/GhyCyp7EWU
Bella Mehta Tweet
bella_mehta
Lots of early pipeline data in lupus at #EULAR2023 mainly in the supplement! AFIMETORAN dual TLR7/8 ANTAGONIST in lupus mice! Maybe steroid sparing! Abst#AB0132 @RheumNow
Bella Mehta Tweet
bella_mehta
#lupus Phase 1 data #EULAR2023 humanised, afucosyl IgG1 antibody against CXCR5 – receptor on B cells and bonafide T follicular helper(Tfh) and circulating T follicular helper-like(cTfh) cells – Potent, tolerated and caused depletion of cells in SLE and RA. Abst#AB0511 @rheumnow
Bella Mehta Tweet
bella_mehta
bone complications #SLE – imp to maintain vitamin D levels! Osteonecrosis of the femoral head (ONFH) and Avascular osteonecrosis (AVN) – total 86 pts – 60 had both ONFN and AVN. ONFN often b/l more morbidity, raynauds and low vit D compared to AVN Abst#AB0566#EULAR2023 @rheumnow
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#EULAR2023 #POS0112 Consistent with clinical response, Post-hoc analyses of Phase 2 RCT of Deucravacitinib (Tyk2-i) showed this therapy suppressed both IFN and B cell pathways - a broader mode of action in reducing #SLE pathophysiology. Look forward to Phase 3 results @RheumNow https://t.co/UoZ2xS3IzC
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#EULAR2023 #POS1147 Primary endpoint for Cenerimod (S1P1 modulator) phase 2 RCT in #SLE was not met after multiple testing. Post-hoc analysis showed greater reduction in SRI-4 and mSLEDAI in IFN-High vs IFN-Low at 6mths. A biomarker to stratify response in Phase 3 @RheumNow https://t.co/wKM5V1JgXT
Janet Pope Tweet
Janetbirdope
#Lupus #nephritis - many trials and this is one company #Roche and other #pharmaceutical CO’s are also involved #Hope #SLE #EULAR2023 ⁊@RheumNow⁩ ⁊@eular_org⁩ https://t.co/Giu2iUqq6j
Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its Faculty.
Janet Pope Tweet
Janetbirdope
Rx of #lupus #SLE The most challenging seems to be longstanding & residual disease activity - damage accumulates over time - esp if #glucocorticoids are used. Consider only as bridging. How to treat #lupus #EULAR2023 Boumpas ⁊@RheumNow⁩ #ClinicalPearl ⁊@eular_org⁩ https://t.co/heBbcRAjxO
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×